206 related articles for article (PubMed ID: 36583004)
1. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
2. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
Chen C; Zhou R; Fu F; Xiao J
Eur Psychiatry; 2023 Nov; 66(1):e99. PubMed ID: 38031404
[TBL] [Abstract][Full Text] [Related]
3. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.
Zhao Z; Tang Y; Hu Y; Zhu H; Chen X; Zhao B
Ann Transl Med; 2021 Sep; 9(18):1482. PubMed ID: 34734034
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
6. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
7. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
9. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
12. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review.
Clemens KK; Ernst J; Khan T; Reichert S; Khan Q; LaPier H; Chiu M; Stranges S; Sahi G; Castrillon-Ramirez F; Moist L;
Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1111-1120. PubMed ID: 37100640
[TBL] [Abstract][Full Text] [Related]
15. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
Dong S; Guo X; Wang H; Sun C
Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
[TBL] [Abstract][Full Text] [Related]
16. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
18. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system.
Yang Z; Yu M; Mei M; Chen C; Lv Y; Xiang L; Li R
Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):504-510. PubMed ID: 34895802
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Yang Z; Lv Y; Yu M; Mei M; Xiang L; Zhao S; Li R
Front Pharmacol; 2022; 13():925377. PubMed ID: 36386208
[No Abstract] [Full Text] [Related]
20. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
